Tourmaline Bio, Inc. (TRML)
2025-06-30 | ||||
|---|---|---|---|---|
| Unrealized loss on investments | -106 | |||
| Other income, net | 2,882 | |||
| Research and development | 19,634 | |||
| General and administrative | 6,340 | |||
| Total operating expenses | 25,974 | |||
| Loss from operations | -25,974 | |||
| Net loss | -23,092 | |||
| Comprehensive loss | -23,198 | |||
| Net loss per share, basic (usd per share) | -0.9 | |||
| Net loss per share, diluted (usd per share) | -0.9 | |||
| Weighted-average, common shares outstanding, basic (in shares) | 25,755,000 | |||
| Weighted-average, common shares outstanding, diluted (in shares) | 25,755,000 | |||